370P Smoking cessation with cytisine in a lung cancer screening program: The RISP trial

20260 citationsJournal Articlegold Open Access

Authors

Massimiliano Cani · University of Turin

D. Bafunno · Istituto Tumori Bari

Francesca Caumo · Istituto Oncologico Veneto

Silvia Novello · University of Turin

Salvatore Cardellicchio · Azienda Ospedaliero-Universitaria Careggi

V. Cilenti

E. Davoli · University of Modena and Reggio Emilia

Abstract

Table: 369P 336 FHC ratio 1 st degree Mean 0.39 (0-1.44)Median 0.35 (0-0.61)FHC ratio 2 nd degree Mean 0.03 (0-0.25)Median 0 (0-0.06)FHC ratio 3 rd degree Mean 0.01 (0-0.15)Median 0 (0-0.02)Total FHC score Mean 0.43 (0-1.48)Median 0.40 (0.12-0.67) 90 th percentile threshold 0.89 (0.62-0.96) 75 th percentile threshold 0.67 (0.62-0.71)Patients included 90 th percentile 33 (9.8%)Patients included 75 th percentile 83 (24.7%) Conclusions:The observational phase of the study shows the potential utility of FHC in selecting NSCLC patients for germline mutation testing.Clinical trial identification: NCT06196424.

Topics & Keywords

Smoking Behavior and Cessation Nicotinic Acetylcholine Receptors Study Cancer, Stress, Anesthesia, and Immune Response

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 11, pp. 106683-106683

DOI: 10.1016/j.esmoop.2026.106683

Field-Weighted Citation Impact: 0.00